| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
Purpose: Recent studies have shown that cyclooxygenase (Cox)-2 may be involved in colorectal carcinogenesis. We aimed to determine whether Cox-2 expression in itself can predict outcome of colorectal cancer patient after surgery. In addition, the expression of Cox-1 was also evaluated.
Experimental Design: Tissue samples of primary and secondary tumors from 288 patients undergoing surgical resections for colorectal adenocarcinoma were immunohistochemically examined for Cox-2 and Cox-1 expressions. The specimens were graded based on the intensity and extent of staining; then, the correlations between Cox-2 and Cox-1 expressions with clinicopathologic parameters and survival time were analyzed.
Results: Expression of Cox-2 was positive in 70.8% of primary tumor, 92.0% of lymph node metastases, 100.0% of hepatic metastases, and was significantly associated with tumor size, depth of invasion, lymph node metastasis, vessels invasion, stage and recurrence. In contrast, Cox-1 was positive in 42.7% of primary tumor, 84.0% of lymph node metastases, 37.5% hepatic metastases, and was associated with only tumor size. Patients with Cox-2–positive tumors had a significant shorter survival time than those with negative tumors did (P = 0.0006 by log-rank test); and, in a multivariate analysis, Cox-2 was an independent prognostic factor (P = 0.0103; relative risk 4.114; 95% confidence interval, 1.397–12.120). Cox-1 status had no statistically effect on patient survival time.
Conclusions: Elevated Cox-2 expression, but not that of Cox-1, was significantly associated with reduced survival and recognized as an independent prognostic factor in our cohort of colorectal cancer patients.
This article has been cited by other articles:
|
|
 |
|
  R. Muthuswamy, J. Urban, J.-J. Lee, T. A. Reinhart, D. Bartlett, and P. Kalinski Ability of Mature Dendritic Cells to Interact with Regulatory T Cells Is Imprinted during Maturation Cancer Res., July 15, 2008; 68(14): 5972 - 5978. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Shen, Z. F. Yang, Y. Gao, J. C. Li, H. X. Chen, C. C. Liu, R. T.P. Poon, S. T. Fan, J. M. Luk, K. H. Sze, et al. The Kringle 1 Domain of Hepatocyte Growth Factor Has Antiangiogenic and Antitumor Cell Effects on Hepatocellular Carcinoma Cancer Res., January 15, 2008; 68(2): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kolev, H. Uetake, S. Iida, T. Ishikawa, T. Kawano, and K. Sugihara Prognostic Significance of VEGF Expression in Correlation With COX-2, Microvessel Density, and Clinicopathological Characteristics in Human Gastric Carcinoma Ann. Surg. Oncol., October 1, 2007; 14(10): 2738 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Nakamoto, H. Uetake, S. Iida, Y. V. Kolev, L. T. Soumaoro, Y. Takagi, M. Yasuno, and K. Sugihara Correlations between Cyclooxygenase-2 Expression and Angiogenic Factors in Primary Tumors and Liver Metastases in Colorectal Cancer Jpn. J. Clin. Oncol., September 10, 2007; (2007) hym080v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. A. Marshall, B. F. Fernandes, S. Di Cesare, S. C. Maloney, P. T. Logan, E. Antecka, and M. N. Burnier Jr The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma Carcinogenesis, September 1, 2007; 28(9): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Chan, S. Ogino, and C. S. Fuchs Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2 N. Engl. J. Med., May 24, 2007; 356(21): 2131 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Heer, M. J.E.M. Gosens, E. C. de Bruin, N. G. Dekker-Ensink, H. Putter, C. A.M. Marijnen, A. J.C. van den Brule, J. H. J.M. van Krieken, H. J.T. Rutten, P. J.K. Kuppen, et al. Cyclooxygenase 2 Expression in Rectal Cancer Is of Prognostic Significance in Patients Receiving Preoperative Radiotherapy Clin. Cancer Res., May 15, 2007; 13(10): 2955 - 2960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mimori, H. Ishii, H. Nagahara, T. Sudo, K. Yamashita, H. Inoue, G. F. Barnard, and M. Mori FHIT Is Up-Regulated by Inflammatory Stimuli and Inhibits Prostaglandin E2-Mediated Cancer Progression. Cancer Res., March 1, 2006; 66(5): 2683 - 2690. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
